

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *				2. Issuer Name and Ticker or Trading Symbol						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
			4	Amr	neal Pha	rmaceu	tica	als, I	nc. [Al	MRX						
(First) (Mid	ldle)	3	3. Da	te of Earlie	est Transa	ction	ı (MM/	DD/YYYY)		_	a titla halam			alam)
						<i>51</i> 0	/2.04	22				Officer (giv	e title below)	iei (specify t	elow)
			/			5/9	/20/	23								
		EVAR		1 I£ A	\ ma am dma am	t Data Or	.i.a.i.a	al Eile	danını	>/\mmax		Individual a	n Ioint/C	roun Eiling	(6) 1 4 1	. 11 1.)
(bite	ct)		2	+. II <i>F</i>	Amenamen	ii, Date Oi	ngm	ai riic	a (MM/DI	J/YYYY) 0.	individual o	or John/G	oup rining	Check Appl	icable Line)
BRIDGEWATER, NJ 08807										_}	X _ Form filed by One Reporting Person Form filed by More than One Reporting Person					
city) (Sta	te) (Zip))]	Rule	10b5-1(c)	Transactio	n In	dicati	on							
				□ Cl	heck this b	ox to indi	cate	that a	transacti	on was	mad	le pursuant to	a contra	ct, instructio	n or writt	en plan
			t	hat is	sintended	to satisfy	the a	ıffirma	ative defe	ense coi	nditi	ons of Rule 1	0b5-1(c)	See Instruc	tion 10.	
	,	Table I -	- Non-D	eriva	ative Secu	rities Acq	uire	ed, Dis	sposed o	f, or Be	nefi	cially Owne	d			
1. Title of Security (Instr. 3)				2A. Deemed Execution Date, if any		3. Trans. Code (Instr. 8)		or Disposed of (D)			Follo	wing Reported T	6. 7. Nature Ownership of Indirect Form: Beneficial Direct (D) Ownership			
						Code	v	Amou		Price					(I) (Instr. 4)	(Instr. 4)
Class A Common Stock 5/10/202			5/10/2023	3		M		80128	3 A	<u>(1)</u>		179274			D	
Tab	le II - Deri	vative S	Securitio	es Be	neficially	Owned (a	e.g. , j	puts,	calls, wa	rrants,	opt	ions, conver	tible secu	rities)		
2. Conversion or Exercise Price of Derivative	3. Trans. Date	Execution	Code	8) Derivative Acquired (Disposed of		Securities A) or of (D)				Securities U Derivative S		derlying curity	Derivative Security (Instr. 5)	derivative Securities Beneficially Owned	Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Security			Cod	e V	7 (A)	(D)						Amount or Number of Shares		Reported	or Indirect	
(1)	5/9/2023		A		76453			(2)	(2)	Comn	ıon	76453	\$0.00	76453	D	
(1)	5/10/2023		М			80128		(3)	<u>(3)</u>	Comn	ıon	80128	\$0.00	0	D	
	(First AL PHAI ROSSING (Stre TER, NJ ity) (Sta 2. Conversion or Exercise Price of Derivative Security	(First) (Michael Cook (Street)	(First) (Middle) AL PHARMACEUTICA ROSSING BOULEVAR (Street) TER, NJ 08807 Fity) (State) (Zip) Table I 2 Cook Table II - Derivative Security 3. Trans. Date Execution Date, if an Execution Date, if an Execution Date of Derivative Security	(First) (Middle) AL PHARMACEUTICALS, ROSSING BOULEVARD (Street) TER, NJ 08807 Sity) (State) (Zip) Table I - Non-D 2. Trans. Da 2. Trans. Da Table II - Derivative Securitic 2. Conversion or Exercise Price of Derivative Security Cod (I) 5/9/2023 A	Ami (First) (Middle) 3. Date AL PHARMACEUTICALS, ROSSING BOULEVARD (Street) 4. If A street in the property of the property	Amneal Pha (First) (Middle) 3. Date of Earlie AL PHARMACEUTICALS, ROSSING BOULEVARD (Street) 4. If Amendment (Street) Check this bethat is intended Table I - Non-Derivative Securities Beneficially 2. Trans. Date Execution Date, if any 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date Execution Date, if any 3. Date OF Earlie 4. If Amendment 2. Trans. Date Execution Date, if any 3. Deemed Execution Date, if any 3. Date OF Earlie 4. If Amendment 5. Number Code Derivative Acquired (Instr. 8) 6. Code UV (A) 6. Code V (A) 6. Code V (A) 6. Code V (A)	Amneal Pharmaceu (First) (Middle) 3. Date of Earliest Transa AL PHARMACEUTICALS, ROSSING BOULEVARD (Street) 4. If Amendment, Date Of Check this box to inditate is intended to satisfy Table I - Non-Derivative Securities Accurate in	Amneal Pharmaceutics (First) (Middle) 3. Date of Earliest Transaction AL PHARMACEUTICALS, ROSSING BOULEVARD (Street) 4. If Amendment, Date Origin TER, NJ 08807 (State) (Zip) Rule 10b5-1(c) Transaction In Check this box to indicate that is intended to satisfy the attended to satisfy th	Amneal Pharmaceuticals, In the	Amneal Pharmaceuticals, Inc. [A] (First) (Middle) 3. Date of Earliest Transaction (MM/DD/YYYY) AL PHARMACEUTICALS, ROSSING BOULEVARD (Street) 4. If Amendment, Date Original Filed (MM/DI ATER, NJ 08807 Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transactithat is intended to satisfy the affirmative defermance of the content of the	Amneal Pharmaceuticals, Inc. [AMRX (First)	Amneal Pharmaceuticals, Inc. [AMRX] (First) (Middle) 3. Date of Earliest Transaction (MM/DD/YYYY) AL PHARMACEUTICALS, (Street) 4. If Amendment, Date Original Filed (MM/DD/YYYY) 6. (Street) 4. If Amendment, Date Original Filed (MM/DD/YYYY) 6. (TER, NJ 08807	Amneal Pharmaceuticals, Inc. [AMRX] Amneal Pharmaceuticals, Inc. [AMRX] X_ Director Officer (giv Street) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Form filed by Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual of X_ Form filed by Securities (Instr. 8) A. If Amendment, Date Original Filed	Amneal Pharmaceuticals, Inc. [AMRX] Amneal Pharmaceuticals, Inc. [AMRX] 3. Date of Earliest Transaction (MM/DD/YYYY) AL PHARMACEUTICALS, ROSSING BOULEVARD (Street) 4. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual or Joint/Gr X_Form filed by One Repor Form filed by One Repor Form filed by More than C Check this box to indicate that a transaction was made pursuant to a contract that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Trans. Date 3. Trans. Date 2. Trans. Date 3. Trans. Date 4. Trans. Date 2. Trans. Date 4. Trans. Dat	Amneal Pharmaceuticals, Inc. [AMRX] (First) (Middle) 3. Date of Earliest Transaction (MM/DD/YYYY) 5. Date of Earliest Transaction (MM/DD/YYYY) 6. Individual or Joint/Group Filing (Street) 4. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual or Joint/Group Filing (Street) 4. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual or Joint/Group Filing (Street) 7. Form filed by One Reporting Person Form filed by More than One Reporting Person Form filed by One Reporting Person Form filed by More than One Reporting Person Form filed by More than One Reporting Person Form filed by One Reporting Person Form filed b	Amneal Pharmaceuticals, Inc. [AMRX] Check all applicable

Explanation of Responses:

- (1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- (2) Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
- (3) On May 9, 2022 the reporting person was granted 80,128 restricted stock units vesting on May 10, 2023.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

Reporting Owners

Reporting Owners								
Reporting Owner Name / Address	Relationships							
Reporting Owner Name / Address	Director 10% Owner Office							
Kiely John								
C/O AMNEAL PHARMACEUTICALS, INC.	X							
400 CROSSING BOULEVARD	21							
BRIDGEWATER, NJ 08807								

/s/ Denis Butkovic, Attorney-in-Fact 5/11/2023

**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

POWER OF ATTORNEY

Know all by these presents that the undersigned, does hereby make, constitute and appoint Denis Butkovic and Chris Daly as a true and lawful attorney-in-fact of the undersigned with full powers of substitution and revocation, for and in the name, place and stead of the undersigned (in the undersigned's individual capacity), to execute and deliver such forms that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Amneal Pharmaceuticals, Inc. pursuant to Sections 13(d), 13(g) and 16(a) of the Securities Exchange Act of 1934, as amended, including without limitation, Schedule 13D, Schedule 13G, Form 3, Form 4 and Form 5 (including any amendments thereto). The Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Schedule 13D, Schedule 13G, Forms 3, 4 and 5 with regard to his or her ownership of or transactions in securities of Amneal Pharmaceuticals, Inc., unless earlier revoked in writing. This Power of Attorney also serves to revoke and replace as of the date hereof, any prior Power of Attorney executed by the undersigned with respect to the ownership of securities of Amneal Pharmaceuticals, Inc. The undersigned acknowledges that Denis Butkovic and Chris Daly are not assuming any of the undersigned's responsibilities to comply with Section 13 or Section 16 of the Securities Exchange Act of 1934, as amended.

By: /s/ John Kiely Name: John Kiely

Date: May 5, 2023